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Summary
 
The serine proteinase inhibitor (serpin) plasminogen activator inhibitor type 2 (PAI-2) is well
characterized as an inhibitor of extracellular urokinase-type plasminogen activator. Here we
show that intracellular, but not extracellular, PAI-2 protected cells from the rapid cytopathic
effects of alphavirus infection. This protection did not appear to be related to an effect on apop-
tosis but was associated with a PAI-2–mediated induction of constitutive low-level interferon
(IFN)-
 
a/b
 
 production and IFN-stimulated gene factor 3 (ISGF3) activation, which primed the
cells for rapid induction of antiviral genes. This primed phenotype was associated with a rapid
development of resistance to infection by the PAI-2 transfected cells and the establishment of a
persistent productive infection. PAI-2 was also induced in macrophages in response to viral
RNA suggesting that PAI-2 is a virus response gene. These observations, together with the re-
cently demonstrated PAI-2–mediated inhibition of tumor necrosis factor-
 
a
 
 induced apoptosis,
(
 
a
 
) illustrate that PAI-2 has an additional and distinct function as an intracellular regulator of
signal transduction pathway(s) and (
 
b
 
) demonstrate a novel activity for a eukaryotic serpin.
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T
 
he serine proteinase inhibitors, or serpins,
 
1
 
 are a large
family of single chain molecules that are structurally
related to 
 
a
 
1-antitrypsin. They participate in the regulation
of proteinase-activated physiological and pathological pro-
cesses, including blood coagulation, fibrinolysis, extracellular
matrix remodelling, prohormone activation, and tumor
metastasis. Ovalbumin is the parent prototype of a distinc-
tive and growing subfamily of serpins, known as ov-serpins
(1). Ov-serpins lack typical, cleavable hydrophobic signal
sequences, which results in inefficient (and often undetect-
able) translocation and secretion, and thus a predominantly
cytoplasmic localization of these proteins. Members of this
subfamily include the viral serpin 
 
crmA
 
, plasminogen acti-
vator inhibitor type 2 (PAI-2), elastase inhibitor, squamous
cell carcinoma antigen, the tumor suppressor maspin, pla-
cental thrombin inhibitor (PI)-6, and the recently described
PI-8 and PI-9 (1–6). The best characterized of these serpins
is the intracellular viral serpin 
 
crmA
 
, which blocks apoptosis
by inhibition of IL-1
 
b
 
–converting enzyme (ICE) and other
related caspases (7). The vaccinia virus–encoded serpin,
B13R (SPI-2), is also an inhibitor of ICE, and blocks both
TNF-
 
a
 
– and FAS-mediated apoptosis (8). Intracellular
functions for some mammalian ov-serpins have been re-
cently postulated (3, 5), suggesting that this family may also
participate in a range of diversified intracellular activities.
PAI-2 was originally characterized as an inhibitor of the
extracellular serine proteinase, urokinase-type plasminogen
activator (uPA) (9). uPA generates plasmin from its precur-
sor plasminogen and regulates extracellular proteolysis in-
volved in tissue remodelling, inflammatory disease, and tu-
mor cell invasion/metastasis. However, the predominant
proportion of newly synthesized PAI-2 remains intracellu-
lar, with only a fraction of PAI-2 under certain circum-
stances being secreted as a glycosylated product (10). Re-
cently, an intracellular role for PAI-2 has been postulated
based on the ability of cytoplasmic expression of PAI-2 to
 
1
 
Abbreviations used in this paper:
 
 CAT, chloramphenicol acetyl transferase;
CPE, cytopathic effect; IRF, interferon response factor; ISGF3, inter-
feron-stimulated gene factor 3; ISRE, interferon-stimulated response ele-
ment; MOI, multiplicity of infection; OAS, oligoadenylate synthetase;
PAI-2, plasminogen activator inhibitor; poly IC, polyinosinic-polycyti-
dylic acid; RRV, Ross River virus; serpin, serine proteinase inhibitor;
TCID
 
50
 
, 50% tissue culture infectivity dose; uPA, urokinase-type plasmin-
ogen activator. 
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Plasminogen Activation Inhibitor Type 2 Induces IFN-
 
a
 
/
 
b
 
protect cells from TNF-
 
a
 
–mediated apoptosis (11, 12).
PAI-2 is rapidly induced in monocytes/macrophages in re-
sponse to TNF-
 
a
 
 and LPS, and Dickinson et al
 
.
 
 (12) have
suggested that the physiological role of intracellular PAI-2
in inflammatory macrophages may be to protect these cells
from the cytotoxic effects of their own TNF-
 
a
 
. A role for
PAI-2 in the inhibition of apoptosis has been supported by
the observation that PAI-2 can inhibit 
 
Mycoplasma avium–
 
induced apoptosis of macrophages (13).
In this study, we show that HeLa cells expressing PAI-2
are protected from the cytopathic effect (CPE) of the al-
phaviruses, Ross River virus (RRV) and Sindbis virus. Al-
phaviruses are single-stranded positive-sense RNA viruses
that induce a rapid, lytic infection in most vertebrate cells
(14). RRV infection did not induce apoptosis in HeLa cells,
indicating that protection against CPE in PAI-2–expressing
cells was unrelated to a PAI-2–mediated inhibition of apop-
tosis. Instead, protection was associated with a PAI-2–medi-
ated induction of constitutive low-level autocrine IFN-
 
a/b
 
production, which primed the cells for rapid, IFN-
 
a/b
 
–inde-
pendent induction of antiviral resistance. Thus, after virus
infection, PAI-2–transfected cells induced antiviral genes
(without further IFN-
 
a/b
 
), which was associated with a
rapid inhibition of viral replication. In contrast, virus infec-
tion of control cells did not result in IFN-
 
a/b
 
 or antiviral
gene induction and was associated with rapid viral replica-
tion and cell death.
Intracellular PAI-2 expression thus produced at least two
potentially related phenotypes, resistance to TNF-
 
a
 
 (11,
12), and induction of constitutive autocrine IFN-
 
a
 
/
 
b
 
priming. These phenotypes are entirely distinct from the
well-characterized effects of extracellular PAI-2 and suggest
that PAI-2 also has an intracellular function as a regulator
of signal transduction pathway(s).
 
Materials and Methods
 
Cells and Cell Culture.
 
Stable, cloned HeLa cell lines express-
ing sense (S1a, S1b) and antisense (A2/7, A2/17) PAI-2 cDNA
were generated as previously described (12) by inserting a DNA
fragment containing the entire PAI-2 coding sequence and the 3
 
9
 
untranslated region in both orientations into the expression vec-
tor, pRcCMV, under control of the constitutive CMV promoter.
As a positive control for an irrelevant gene, the coding sequence
for the chloramphenicol acetyl transferase (CAT) gene was in-
serted into the same vector. Stable transfectants containing these
constructs and vector alone (CMV) were selected by resistance to
G418 and characterized by Northern and immunoblot analyses
(12). The human macrophage cell line, MonoMac6, was obtained
from Professor H.W.L. Ziegler-Heitbrock, University of Munich
(Munich, Germany; reference 15). All cell lines were cultured in
RPMI 1640 medium supplemented with 10% fetal calf serum, 60
 
m
 
g/ml penicillin G, and 100 
 
m
 
g/ml streptomycin sulfate, and
were maintained at 37
 
8
 
C in a 5% CO
 
2
 
 and 95% air atmosphere.
The transfected HeLa lines were also maintained with 200 
 
m
 
g/ml
G418, which was removed at least 48 h before their use in an ex-
periment. Cells (
 
z
 
10
 
7
 
) were treated with 500 U/ml human IFN-
 
g
 
(Boehringer Mannheim GmBH, Mannheim, Germany), 500 U/ml
IFN-
 
a
 
–2B (Intron A; Schering-Plough, Pty. Ltd., New South
Wales, Australia), or 20 
 
m
 
g/ml polyinosinic-polycytidylic acid
(poly IC) (Sigma Chemical Co., St. Louis, MO) for the times in-
dicated. All cell lines were checked routinely and determined to
be mycoplasma free.
 
Virus Infections.
 
The following viruses were used in this
study: RRV, T48 strain, stock 10
 
8
 
 supplied at 50% tissue culture
infectivity dose (
 
TCID
 
50
 
) per ml (16); Sindbis virus, 
 
z
 
10
 
8
 
 PFU/
ml (17), obtained from Professor D.E. James (University of
Queensland, Brisbane, Australia); Adenovirus 5, 10
 
8
 
 infectious
doses per ml (18); Influenza virus (reassortant with external anti-
gens from A/Taiwan/1/86 and internal antigens from A/PR/8/34),
10
 
9
 
 egg infectious U/ml, supplied as an egg allantoic fluid–
derived stock by A. Hampson (CSL Ltd., Parkville, Australia);
Vaccinia virus, thymidine kinase negative WR strain, stock sup-
plied at 10
 
9 
 
PFU/ml (19). The multiplicity of infection (MOI)
was based on the units given for each virus; thus, MOI 1 (or log
MOI 0) for RRV was 1 
 
TCID
 
50
 
/cell, whereas MOI 1 for vac-
cinia virus refers to 1 PFU/cell.
 
Cell Survival Assays.
 
Cell survival was quantitated by both
crystal violet staining and tetrazolium dye–based MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assays.
Cell lines were plated into 96-well plates at 2 
 
3 
 
10
 
4 
 
cells/well in
duplicate or triplicate and allowed to adhere overnight. After ad-
dition of virus, the plates were incubated at 37
 
8
 
C for 7 d or for
the indicated time period before staining with crystal violet or
MTT assay. For the crystal violet assay, medium was removed
and the cells were stained for 15 min with 0.05% crystal violet in
10% formaldehyde. The plates were then washed with water and
dried, and 100 
 
m
 
l of 100% methanol was added to dissolve the
dye, then the OD at 595 nm was measured using a Bio-Rad
ELISA plate reader (Bio-Rad, Hercules, CA). The MTT assay
was performed as previously described (12) with cells plated as
above. Cell survival for both assays was expressed as a percentage
calculated as OD of experimental wells/OD of control wells.
 
RRV Virus Titration (TCID
 
50
 
) and Immunofluorescent Antibody
Staining.
 
The TCID
 
50
 
 assay was performed in duplicate using
10-fold serial dilutions of 100 
 
m
 
l of sample supernatants in 96-
well flat-bottomed plates. Vero cells (2 
 
3 
 
10
 
4
 
 cells in 100 
 
m
 
l)
were then added into each well and the plates were incubated at
37
 
8
 
C for 7 d. The plates were stained with 0.05% crystal violet in
10% formaldehyde and the RRV titer was expressed as a TCID
 
50
 
(16).
For indirect immunofluorescence staining, cells cultured on
coverslips were fixed in cold 1:1 (vol/vol) acetone/methanol for
2 min, washed in PBS, blocked with 10% FCS, and stained with
a rabbit polyclonal anti-RRV sera (gift from Dr. J. Aaskov,
Queensland University of Technology, Brisbane, Australia), fol-
lowed by an anti–rabbit FITC-labeled F(ab
 
9
 
)
 
2
 
 (Silenus Labs.,
Hawthorn, Australia).
 
Immunoblot Analyses.
 
For immunoblot analyses of whole cell
lysates, cells were plated at 0.5–1 
 
3 
 
10
 
6
 
 cells/well per 6-well plate
and infected with RRV (MOI 1) for 90 min at 37
 
8
 
C followed by
washing. At the indicated time points, cell monolayers were
washed three times in PBS and harvested by gentle scraping into
cold PBS. The cells were pelleted by centrifugation and quickly
lysed in cold PBS containing 0.5% Triton X-100, 5 mM EDTA,
and 20 
 
m
 
g/ml of the proteinase inhibitor, 4-(2-aminoethyl)ben-
zenesulfonylfluoride (AEBSF). Cell debris was removed by cen-
trifugation at 12,000 
 
g
 
 for 10 min, and the protein concentration
of each sample was determined by Bio-Rad protein assay (Bio-
Rad). The solubilized proteins (60 
 
m
 
g) were separated by SDS-
PAGE under nonreducing conditions using a 10% acrylamide
gradient gel, and the proteins were electrophoretically blotted 
1801
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onto a nitrocellulose membrane (Bio-Rad) for 16 h at 30 V. Spe-
cific antigens were detected by incubation for 1 h with polyclonal
rabbit anti-RRV antisera, 1 
 
m
 
g/ml anti–PAI-2 monoclonal anti-
body (American Diagnostica, Epping, Australia), 1 
 
m
 
g/ml anti-
 
bcl-2
 
 monoclonal antibody (Oncogene Sciences, Uniondale,
NY), or 1 
 
m
 
g/ml anti–
 
a
 
-tubulin antibody (Sigma Chemical Co.).
Antibody binding was visualized by ECL detection (Amersham
International, Little Chalfont, UK) and membranes were exposed
to Kodak XK-1 film (Eastman Kodak Co., Rochester, NY).
For immunoblot analysis of nuclear and cytoplasmic lysates,
extracts were prepared as previously described (20), except that
nuclei were obtained using 0.15% NP-40 in the lysis buffer. Pro-
tein extracts were electrophoretically separated on 8% SDS-poly-
acrylamide gels, blotted to nitrocellulose membranes, and probed
with 2 
 
m
 
g/ml anti–interferon-stimulated gene factor 3 (ISGF3)
 
g
 
polyclonal antibody (C-20) (Santa Cruz Biotech, Santa Cruz,
CA) or 2 
 
m
 
g/ml anti–interferon response factor (IRF)-1 poly-
clonal antibody (C-20) (Santa Cruz Biotechnology).
 
EMSA Assays.
 
Protein–DNA complexes were formed in 20-
 
m
 
l
reaction mixtures containing 12 mM Hepes, pH 7.9, 30 mM
KCl, 0.06 mM EDTA, 0.06 mM EGTA, 1 mM MgCl
 
2
 
, 2.5% Fi-
coll, 0.5 mM dithiothreitol, 2 
 
m
 
g poly [d(I)–d(C)] (Boehringer
Mannheim Australia Pty. Ltd., Castle Hill, Australia), and 20 
 
m
 
g
nuclear extract, to which 1 
 
m
 
l of purified 
 
32
 
P-radiolabeled oligo-
nucleotide was added. Complexes formed after 20 min on ice
were resolved on 5% polyacrylamide gels at 150 V in TBE (100
mM Tris HCl, 100 mM Borate, and 2 mM EDTA, pH 8.3).
Double stranded oligonucleotides were radiolabeled with T4
polynucleotide kinase (New England Biolabs, Beverly, MA) and
 
g
 
-[
 
32
 
P]ATP (6000 Ci/mmole, Amersham International). The oli-
gonucleotides, containing the interferon-stimulated response element
(ISRE) consensus binding motif (21) were as follows: forward,
5
 
9
 
GTTCGGGAAAGGGAAACCGAAACTGAAGCC3
 
9
 
; and re-
verse, 5
 
9
 
GATCGGCTTCAGTTTCGGTTTCCCTTTCCC3
 
9
 
.
Mutant oligonucleotides containing changes in the ISRE consensus
sequence were used in gel shift assays to confirm the specificity of the
binding interactions (data not shown). Immunoblotting of EMSA
gels was performed as described by Demczuk et al
 
.
 
 (22) using
2 
 
m
 
g/ml anti-ISGF3
 
g
 
 antibody (Santa Cruz Biotech).
 
Recombinant PAI-2.
 
Purified recombinant PAI-2 was pro-
vided by Biotech Australia Pty. Ltd. (Sydney, Australia) and had a
specific activity of 150,000 IU/mg as assayed for inhibitory activ-
ity against uPA using the Spectrolyse
 
Ò
 
 
 
Urokinase assay (American
Diagnostica).
 
IFN-a and IFN-b reverse transcriptase (RT)-PCR. Cell lines (5 3
106cells/well per 6-well plate) were plated 48 h before addition of
RRV (MOI 1) or 5 mg/ml poly IC (Boehringer Mannheim). Af-
ter 8 h, the medium was removed and the cells lysed with 1 ml
Total RNA Isolation Reagent (Advanced Biotechnologies Ltd.,
Surrey, UK). After extraction, the RNA was reverse transcribed
at room temperature for 20 min and then at 408C for 1 h in a 20
ml reaction containing 1 mg RNA, 1 mg random hexamer prim-
ers (Boehringer Mannheim), 1 ml 10 mM dNTP (Promega,
Madison, WI) and the following from the SuperscriptÔ II RT
kit (GIBCO BRL, Bethesda, MD): 4 ml 53 first strand buffer, 2
ml 0.1 M dithiothreitol, and 1 ml SuperscriptÔ II RNase2 RT.
Control reactions contained no RT. After hydrolysis of the RNA
with sodium hydroxide, the cDNA was purified by QIAquick-
spin PCR Purification (QIAGEN, Clifton Hill, Australia) and
eluted in 50 ml.
PCR for IFN-a and IFN-b was performed in a 20-ml reaction
volume containing 1 ml cDNA and 0.5 ml IFN-a primers (forward:
59CAGGAGGAGTTTGATGGCAACCAG39; reverse: 59GAC-
AACCTCCCAGGCACAAGGGC39; Stratagene, La Jolla, CA),
or 0.5 ml (10 mM) of each of the IFN-b primers (forward:
59ATGACCAACAAGTGTCTCCTCCAAA39; reverse: 59GTC-
TGAATGTCCAATGGAGGCTTTG39) or b actin primers
(forward: 59CACAGAGCCTCGCCTTTG39; reverse: 59GTA-
CATGCAACGATAGGT39) (23). Each PCR reaction for IFN-a
and b actin contained 0.3 ml (2,500 U/ml) AmpliTaq DNA
polymerase, 2 ml 103 AmpliTaq PCR Buffer II (Perkin-Elmer,
Norwalk, CT), 1.1 ml 25-mM MgCl2, and 0.4 ml dNTPs. PCR
was performed using a GeneAmp PCR system 9600 with 5 min
of denaturation at 958C, followed by 35 cycles at 948C for 45 s,
648C for 45 s, and 728C for 90 s, followed by a 10 min extension.
The PCR reaction for IFN-b contained 0.2 ml (2 U/ml) Dy-
NAZyme II DNA polymerase, 2 ml DyNAZyme 103 buffer
(Finnzymes Oy, Espoo, Finland), and 1.2 ml dNTPs. PCR was
performed with a 2-min denaturation at 958C, followed by 35
cycles at 948C for 30 s, 558C for 30 s, and 728C for 1 min, fol-
lowed by a 10 min extension at 728C. Amplification products
were resolved by agarose gel electrophoresis and stained with
ethidium bromide.
IFN-a/b Bioassay. Bioactive IFN-a/b was measured by
CPE inhibition bioassay using Sindbis virus infection of Vero
cells, a cell line defective for IFN-a/b production. Duplicate 10-
fold serial dilutions of test supernatants were cultured with Vero
cells (104/well in 96-well plates) for 24 h. Sindbis virus was then
added at a MOI 1 and after 4 d the plates were stained with crys-
tal violet. The assay was standardized against recombinant IFN-
a2B (Intron A; Schering-Plough Pty. Ltd.) and had a detection
sensitivity of 10 IU/ml. A 50% reduction in viral CPE was ob-
tained at 25 IU/ml. RRV containing supernatants were exposed
to 960 mW/cm2 UV-C for 2 h to inactivate the RRV (16) before
addition to Vero cells.
Supernatant Transfers. T75 flasks containing S1b and A2/7
cells were maintained in standard medium until the cultures had
become overconfluent. The medium was then replaced with 10
ml RPMI 1640 and supplemented with antibiotics and 1% FCS.
After 24 h the supernatant was removed, and cell debris was re-
moved by spinning at 2000 g for 20 min and passing the superna-
tants through a 0.22-mM filter. The supernatants were then con-
centrated using a Centricon 10 concentrator (Amicon Inc.,
Beverly, MA). The unconcentrated supernatant and the concen-
trates from A2/7 and S1b cells were then added separately in qua-
druplicate to 103 A2/7 cells that had been seeded in wells of a flat
96-well plate the day before. After overnight incubation at 378C,
200 ml of RPMI 1640, supplemented with antibiotics and 10%
FCS, was added and the cells were infected with RRV, MOI 5 1.
The plates were then stained with crystal violet on day 3. Per-
centage of cell survival was calculated as mean OD595 of test cells/
mean OD595 of cells which had received medium instead of su-
pernatant and were not infected with RRV.
Treatment of S1b Cells with Anti–IFN-a/b Antibody. 200 S1b
cells were seeded per well in a 96-well plate in triplicate and cul-
tured overnight in standard medium, after which the cells were cul-
tured in 100 ml RPMI 1640 (supplemented with antibiotics) con-
taining 1% by volume polyclonal rabbit anti–human IFN-aA (106
neutralizing U/ml) and 4% polyclonal sheep anti–human IFN-b
(5 3 104 neutralizing U/ml) (BioSource Int., Camarillo, CA).
Control cells were cultured in 1% normal rabbit serum and 4%
normal sheep serum. Every 3–4 d the cells were scrapped from
the well, disaggregated by repeated pipetting, and reseeded at 200
cells/well. After 18 d, 100 ml of standard medium with 10% FCS
was added and the cells were infected with RRV MOI 5 1. Af-
ter 6 d, cell survival was monitored by crystal violet assay and the1802 Plasminogen Activation Inhibitor Type 2 Induces IFN-a/b
percentage of cell survival was calculated as a percentage of mean
OD595 of test cells/mean OD595 of control cells which had been
cultured in 1% normal rabbit serum and 4% normal sheep serum
and were not infected with RRV.
Northern Blot Analysis. For Northern blotting of MonoMac6
cells, 107 cells were infected in 10-ml round-bottomed tubes with
RRV (MOI 1) for 1 h at 378C with shaking every 15 min, fol-
lowed by three washes before culture at 378C. Infection of
MonoMac6 cells by antibody-dependent enhancement using
subneutralizing levels of antibody was performed as previously
described (16). MonoMac6 cells were also treated with 100 mg/ml
poly IC, 30 ng/ml PMA, or 1 mg/ml LPS. UV-inactivated RRV
was prepared as previously described (16). After 4 h the cells were
pelleted and RNA was isolated as above. Purified total RNA was
electrophoresed on denaturing agarose gels containing 1.1%
formaldehyde. The gel was stained with ethidium bromide as a
measure of total RNA loaded in each lane. RNA was transferred
to Hybond N nylon membranes (Amersham International) by
capillary diffusion as described previously (12). The blots were
probed with a radiolabeled 2.0-kb HindIII/EcoR1 DNA frag-
ment encoding PAI-2 cDNA (3).
For Northern blotting of S1b and A2/7 cells, 107 cells were in-
fected with RRV (MOI 5 1) and cultured for the times indicated
before isolation of RNA as described above. Blots were probed
with a radiolabeled 300-bp PvuII/EcoRI DNA fragment encod-
ing 2959oligoadenylate synthetase (OAS) cDNA (24). Signals
were quantitated using a scanning densitometer (Molecular Dy-
namics, Victoria, Australia) driven by ImageQuant software.
Results
HeLa Cells Expressing PAI-2 Were Protected from the CPE
of Certain Viruses. We have previously shown that HeLa
cells stably transfected with PAI-2 were protected from ap-
optosis induced by TNF-a (12). To explore a possible role
for PAI-2 in protection against virus induced apoptosis,
PAI-2–expressing HeLa cell lines were infected with a
panel of cytopathic viruses which have been reported to
kill cells by induction of apoptosis: alphavirus (25); ade-
novirus (26); influenza (27); and vaccinia (28). HeLa cells
stably expressing PAI-2 (S1a, S1b), antisense PAI-2 mRNA
(A2/7, A2/17), the negative control expressing CAT, and
HeLa cells transfected with plasmid vector alone (CMV)
(12) were infected with 10-fold serial dilutions of adenovi-
rus, influenza virus, vaccinia virus, and two alphaviruses,
RRV and Sindbis. The percentage of cells surviving the vi-
rus-induced CPEs after 7 d was measured by crystal violet
assay (Fig. 1). The PAI-2–expressing cells (S1a, S1b) were
considerably less sensitive than control cell lines (A2/7,
A2/17, CAT, CMV) to the CPE induced by the alphavi-
ruses and adenovirus. The effect was particularly pro-
nounced for RRV, where the PAI-2–expressing lines were
resistant to 105 more virus than were the control lines.
PAI-2 Expression Changed the Rapid Lytic Alphavirus Infec-
tion into a Persistent Productive Infection. To explore further
the pronounced protective effect of PAI-2 expression
against RRV-induced CPE, the survival of infected cells
was monitored over 7 d (Fig. 2 A). RRV produced the
characteristic rapid lytic infection in A2/7, A2/17, and
CAT cell lines, resulting in complete cell death by day 4. In
contrast, RRV-infected S1a and S1b cultures showed no
detectable change in cell survival compared with unin-
fected cultures (Fig. 2 A). Analysis of RRV replication and
cell infection for RRV infected A2/7 and S1b cultures
over an extended period showed that 80% of A2/7 cells
were infected on day 2, resulting in a high virus yield (Fig.
2 B). By day 7, a complete loss of virus production was ob-
served, consistent with the widespread CPE and cell death
Figure 1. PAI-2–expressing
HeLa cell lines are protected
from the CPEs of some viruses.
Each of the indicated HeLa cell
lines were seeded into 96-well
plates in duplicate at 2 3 104
cells/well and were infected after
10–24 h with 10-fold serial dilu-
tions of the indicated virus stock.
S1a and S1b are PAI-2–express-
ing cell lines and A2/7, A2/17,
CAT, and CMV are controls
which do not express PAI-2 (see
Materials and Methods). The
multiplicity of infection (MOI) is
expressed as a log value, thus log
MOI of 0 represents 1 virus unit
per cell (see Materials and Meth-
ods for different units) and log
MOI -7 refers to seven 10-fold
serial dilutions of log MOI 0.
Cell survival was measured after
7 d by crystal violet assay and is
expressed as percent survival rel-
ative to untreated cells.1803 Antalis et al.
seen in Fig. 2 A. In contrast, 5–10% of S1b cells were ini-
tially infected but this fell to a consistent level of ,1% after
a few days (Fig. 2 B). These data illustrated that the classical
rapid lytic alphaviral infection of control cultures was con-
verted to a persistent productive infection in PAI-2–expressing
S1b cells. In addition, the development of resistance to in-
fection in S1b cultures illustrated that these cells were not
innately resistant to infection but developed antiviral activ-
ity after exposure to virus.
PAI-2 Did Not Inhibit RRV Structural Polyprotein Cleavage.
Alphavirus replication involves the synthesis of two polypro-
teins, the nonstructural polyprotein, which is produced in
low abundance and is not readily detected by immunoblot-
ting, and the structural polyprotein, which includes the surface
glycoproteins E1 and E2, the E3 protein, and the capsid.
Individual proteins are generated from the polyproteins by
specific proteolytic cleavages (29). To determine whether
PAI-2 might be interfering with these proteolytic events
and thereby inhibiting viral replication, protein extracts
from RRV-infected S1b and A2/7 cells were analyzed by
immunoblotting using a polyclonal antibody generated against
RRV viral proteins (Fig. 3). The immunoblots showed no
evidence for inhibition of structural polyprotein cleavage
by the presence of PAI-2, with no accumulation of the un-
cleaved precursors, p95 or pE2, evident in S1b cells. Con-
sistent with the higher level of RRV infection in A2/7
cells detected by indirect immunofluorescence (Fig. 2 B),
the extracts from A2/7 cells contained more RRV proteins
relative to S1b cell extracts at each time point.
PAI-2 Did Not Protect S1b Cells from RRV-induced CPE
by Inhibiting Apoptosis. Since HeLa cells expressing PAI-2
(S1a, S1b) were resistant to TNF-a–mediated apoptosis
Figure 3. Protein expression
in S1b and A2/7 cell lines infected
with RRV. PAI-2–expressing
(S1b) and nonexpressing (A2/7)
cell lines were seeded into 6-well
plates (5 3 106 cells/well in du-
plicate), infected at MOI 5 1 for
90 min, and extracellular virus
was removed by five washes. At
the indicated times, the cells were
harvested and protein extracts
were electrophoretically separated
by SDS-PAGE and immunoblot-
ted. Identical blots were probed
with antibodies directed against
RRV proteins, PAI-2, and bcl-2
(see Materials and Methods). The
RRV proteins are p95 (the capsid-
E1-E2-E3 polyprotein); pE2 (pre-
E2); E1 and E2 (the structural surface proteins of the virus); the capsid (which is cleaved from the capsid-E1-E2-E3 polyprotein); and E3, which does not
become part of the final virion. Equal amounts of protein as determined by Bio-Rad protein assay were loaded in each lane and the blots were reprobed
with anti–a-tubulin as a control for protein loading in each lane.
Figure 2. Cell survival and RRV infection in PAI-2–expressing and
control HeLa cell lines. (A) Time course of cell survival. The survival of
the panel of cell lines infected (dashed lines) or not infected (solid lines) with
RRV was assayed daily in replicate plates using the MTT assay. RRV in-
fection was at MOI 5 1. (B) Time course of RRV infection. RRV repli-
cation (TCID50) and percentage of cells infected (estimated by indirect
immunofluorescence on replicate cultures and indicated by % and arrow)
was monitored for RRV-infected S1b and A2/7 cell lines. PAI-2–expressing
(S1b) and nonexpressing (A2/7) cell lines were seeded into 24-well plates,
106 cells/well in duplicate, and infected at MOI 5 1 for 90 min. Free vi-
rus was removed by five washes and at the indicated time points, 100 ml
was removed for viral titer assay. Medium was changed every 3 d and S1b
cultures were split 1 in 3 every 4–5 d after day 6.1804 Plasminogen Activation Inhibitor Type 2 Induces IFN-a/b
(12), the resistance of these cells to alphavirus-induced CPE
(Fig. 1) may suggest that PAI-2 expression protected HeLa
cells from RRV-induced CPE by inhibiting apoptosis. In a
potentially related alphavirus system, Sindbis virus infection
of the AT3 prostate carcinoma cell line induces apoptosis,
which can be inhibited by expression of bcl-2 (24, 30).
However, in contrast to Sindbis virus infection of AT-3
cells, several lines of evidence indicated that PAI-2 did not
inhibit RRV-induced apoptosis, as follows. (a) Electron
micrographic analysis of RRV-induced CPE in A2/7 and
S1b cells showed no evidence of the distinctive ultrastruc-
tural morphology characteristic of apoptosis, such as chro-
matin condensation and margination and cytoplasmic shrink-
age (data not shown). (b) PAI-2 expression did not protect
from infection with influenza virus, a virus demonstrated to
induce apoptosis in HeLa cells (27). (c) Expression of bcl-2
did not correlate with sensitivity of HeLa cells to RRV-
induced CPE or with expression of PAI-2 (Fig. 3). (d) Al-
though cleavage of PAI-2 has been reported to be a marker
of apoptosis in human myeloleukemic cells (31), S1b cul-
tures showed no evidence of changes in PAI-2 protein ex-
pression, or cleavage of PAI-2 after RRV infection (Fig.
3). (e) Pretreatment of A2/7 cells with inhibitors of Sindbis
virus induced apoptosis of AT-3 cells, N-acetylcysteine (25
mM) and pyrrolidine dithiocarbamate (150 mg/ml) (30), fol-
lowed by addition of RRV (as for Fig. 1), did not prevent
RRV-induced CPE of A2/7 cells (data not shown).
Extracellular PAI-2 was not responsible for protection
against RRV mediated CPE. Our previous data suggested
that PAI-2 inhibition of TNF-a–mediated apoptosis was
mediated by intracellular PAI-2 (12), which contrasts with
the ability of 100 ng/ml (170,000 IU/mg) of PAI-2 added
extracellularly, to prevent Mycobacterium avium–induced ap-
optosis of macrophages (13). In contrast to the latter obser-
vations, extracellular PAI-2 did not protect against RRV-
mediated CPE, as no protection against RRV-mediated
CPE was observed when up to 8,000 ng/ml recombinant
PAI-2 was added to A2/7 cells for 24 h before infection
with RRV (Fig. 4). Increasing the preincubation time to
48 h had no effect on this result (data not shown).
PAI-2 was not detectable in concentrated S1b culture
supernatants as measured by immunoprecipitation/immu-
noblot and ELISA analyses (data not shown). In addition,
inhibition of possible cell surface PAI-2 activity by addition
of uPA, a serine proteinase that forms an essentially irre-
versible 1:1 complex with PAI-2, also failed to abolish
resistance of S1b cells to RRV CPE (Fig. 4). Taken to-
gether, these data indicated that neither extracellular nor
cell surface PAI-2 were involved in protection against RRV-
induced CPE.
PAI-2–expressing HeLa Cells, unlike Control HeLa Cells,
Were Primed to Respond to poly IC. Several lines of evi-
dence implicated IFN-a/b and/or IFN-a/b induced anti-
viral genes in the protection mediated by PAI-2 against al-
phavirus-induced CPE: (a) alphaviruses are well known to
be highly sensitive to the antiviral activity of IFN-a/b,
with as little as 2 IU/ml IFN-a significantly inhibiting al-
phaviral replication in HeLa cells (32); (b) influenza and
vaccinia viruses are known to be able to evade IFN-a/b
induced antiviral activity in HeLa cells (32, 33) and PAI-
2–expressing cells were not protected from CPE induced
by these viruses (Fig. 1); and (c) IFN-a/b–induced genes
have a well established role in the maintenance of persistent
infections in vitro (34) and such infections could be estab-
lished in PAI-2–expressing cells (Fig. 2 B). However, HeLa
cells do not normally synthesize IFN-a/b even after virus
infection or treatment with the synthetic dsRNA analogue,
poly IC, unless they have first been primed with IFN (35).
How priming operates is not fully understood; however,
one of the consequences of IFN priming in HeLa cells is
the induction of ISGF3g (36, 37). ISGF3g combines with
activated ISGF3a to form the active transcription factor
complex ISGF3. This complex is reported to be responsible
for autocrine amplification of IFN-a/b expression (38) and
therefore ISGF3g induction may be required before virus
or poly IC can induce IFN-a/b production in HeLa cells.
As expected for unprimed HeLa cells (35), no constitu-
tive IFN-a/b bioactivity was detected in the supernatants
of HeLa, A2/7, or CAT cells, and none was detected after
poly IC treatment (Fig. 5 A). No constitutive IFN-a/b
bioactivity was detected in S1b culture supernatants, but, a
dramatic production of IFN-a/b followed exposure of S1b
cells to poly IC (Fig. 5 A). These data clearly illustrated that
PAI-2–expressing S1b cells were primed for IFN-a/b pro-
duction. The implication from this observation was that
PAI-2 expression induced autocrine IFN-a/b production
below the level detectable by the bioassay (z10 IU/ml) but
at a level sufficient to prime the S1b cells. In HeLa (35) and
other cells (39), priming by IFN-a/b treatment is known
to confer the ability to synthesize IFN-a/b after poly IC
treatment.
Perhaps unexpectedly, IFN-a/b bioactivity was not de-
tected in supernatants from PAI-2–expressing S1b cells af-
ter RRV infection (Fig. 5 A). Thus the priming phenom-
ena resulted in IFN-a/b production after poly IC treatment
but not RRV infection. This data indicated that viral in-
duction of IFN-a/b was not responsible for protection
from alphaviral CPE, but that S1b cells were protected as a
consequence of being primed. Primed cells have been
demonstrated to induce protective (IFN-a/b–inducible)
antiviral genes after viral infection, without induction of
further IFN-a/b production (see Discussion).
Figure 4. Extracellular PAI-2
was not implicated in protection
against CPE. S1b and A2/7 cells
were seeded into 96-well plates
in duplicate at 2 3 104 cells/
well. RRV (MOI 5 1) was
added where indicated and cells
incubated at 378C for 7 d before
measurement of CPE by crystal
violet assay. A2/7 cells were pre-
treated for 24 h with recombinant
PAI-2 (8 mg/ml). S1b cells were incubated with uPA at 500 ng/ml for the
7-d CPE assay. Cell survival is expressed as percentage of survival relative
to untreated cells.1805 Antalis et al.
Detection of IFN-a/b mRNA by RT-PCR in PAI-
2–expressing Cells. The previous data (Fig. 5 A) suggested
that PAI-2–expressing cells have a primed phenotype. This
phenotype is a known consequence of prior exposure to
IFN-a/b (35), suggesting that PAI-2–expressing cells may
produce autocrine IFN-a/b at levels not detectable by the
bioassay. A more sensitive method for detection of cyto-
kines is the use of RT-PCR technology, whereby cytokine
mRNA is amplified using specific oligonucleotide primers
in RT-PCR assays (23). These RT-PCR assays were per-
formed using standard conditions and the quality and the
quantity of the cDNA was assessed by the amplification of
b actin in the same samples. However, the RT-PCR re-
sults should be considered qualitative. Examination of
mRNA isolated from S1b and A2/7 cells showed that S1b
cells constitutively expressed both IFN-a and IFN-b
mRNAs, whereas in A2/7 cells no IFN-b and only a weak
IFN-a signal was detectable (Fig. 5 B, control). (The PCR
amplification efficiency differs considerably for IFN-a and
IFN-b mRNA transcripts, so different intensities for the
respective amplification products should not be interpreted
as demonstrating different relative levels of these two cy-
tokines.) The increase in the intensities of the IFN-a and
IFN-b mRNAs detected in S1b cells in response to poly
IC, but not RRV, infection was consistent with IFN-a/b
bioactivity seen in the Vero cell assay (Fig. 5 A).
The detection of more IFN-a/b mRNA in PAI-
2–expressing cells strongly supported the contention that
S1b cells produced low levels of autocrine IFN-a/b,
which was responsible for the primed phenotype demon-
strated in Fig. 5 A.
Concentrated Supernatants Transferred Antiviral Activity.
If S1b cells secrete low levels of IFN-a/b, which leads to
protection against RRV CPE, protective activity should be
transferable in tissue culture supernatants from S1b cells.
Although transfer of neat (13) supernatants from S1b cells
to A2/7 cells did not protect the A2/7 cells from RRV
CPE, preincubation of A2/7 cells with S1b supernatants
concentrated 15- and 30-fold conferred 44 and 100% pro-
tection to RRV-infected A2/7 cells, respectively (Fig. 5
C). Similar supernatants from A2/7 cells and control super-
natant (medium) failed to provide any significant protection
from RRV-mediated CPE (Fig. 5 C). Thus, concentrated
supernatants from S1b cells were able to confer antiviral re-
sistance to A2/7 cells further supporting a role for autocrine
IFN-a/b.
Treatment of S1b Cells with Anti–IFN-a/b Antibodies. If
S1b cells are protected from RRV–induced CPE by low-
level autocrine IFN-a/b priming, then incubation of S1b
cells with anti–IFN-a/b antibodies should block autocrine
IFN-a/b bioactivity and confer sensitivity to RRV-
induced CPE. However, incubation of S1b cells with anti–
IFN-a/b antibodies for 48 h failed to confer sensitivity
(Fig. 5 D). In addition, short-term (24 h) treatment of S1a
and S1b cells with inhibitors of IFN-a/b signal transduc-
tion (2-aminopurine and staurosporine) also failed to in-
duce sensitivity to RRV-mediated CPE. Long-term expo-
sure was found to be toxic and inhibited viral replication
(data not shown). However, the primed phenotype is
known to persist for up to 18 d in the absence of IFN-a/b
(40). Therefore, autocrine IFN-a/b activity was blocked
by incubation of S1b cells in the presence of anti–IFN-a/b
antibodies for 18, 21, and 25 d. A low cell density was used
to allow access of antibody to the basolateral cell surfaces.
After the indicated number of days, the cells were infected
with RRV and left for 6 d. S1b cells treated with nonneu-
tralizing, control antibody remained protected against CPE,
whereas cells treated for extended periods with anti–IFN-
a/b antibodies showed significant CPE (Fig. 5 D).
Figure 5. The role of IFN-a/b. (A) Bioassay of IFN-a/b protein activ-
ity in the supernatants of S1b, A2/7, CAT, and parental HeLa cell lines.
Cells were cultured for 24 h in the presence of medium alone, RRV
(MOI 5 1), or 20 mg/ml poly IC. Assays were performed in triplicate and
error bars represent SD. (B) Assay by RT-PCR for IFN-a, IFN-b, and b
actin mRNAs in S1b and A2/7 cells 24 h after treatment with medium
alone (control), RRV (MOI 5 1), or poly IC (20 mg/ml). As the PCR
amplification efficiency is quite different for IFN-a and IFN-b mRNA
transcripts, the different intensities for IFN-a and IFN-b amplification
products do not necessarily demonstrate different relative levels of these
two cytokines. (C) Transfer of supernatants from S1b cell and A2/7 cells
onto A2/7 cells followed by infection with RRV. Neat (13) or 15- or
30-fold concentrated 24-h supernatants from S1b and A2/7 were added
to A2/7 cells overnight before infection with RRV (MOI 5 1). Control
represents addition of medium rather than supernatant followed by RRV
infection. Cell survival was determined by crystal violet assay and is ex-
pressed as a percentage of A2/7 cells, which were incubated with medium
and were not infected with RRV (NO RRV). (Supernatant alone in the
absence of RRV had no significant effect on cell survival; data not
shown). (D) Long-term incubation of S1b cells with anti–IFN-a and
anti–IFN-b antibodies. S1b cells were maintained at low cell density in
the presence of anti–IFN-a/b antibodies (anti–IFN-ab 1 RRV) or con-
trol antibody (control antibody 1 RRV) for the indicated number of days
(gray bars, day 2; hatched bars, day 18; black bars, day 25) followed by infec-
tion with RRV; MOI 5 1. S1b cells were also incubated with anti–IFN-
a/b antibodies without RRV infection (anti–IFN-a/b NO RRV). Cell
survival was measured on day 6 using the crystal violet assay and was ex-
pressed as a percentage of the survival of cells that had been incubated
with control antibody and that had not been infected with RRV.1806 Plasminogen Activation Inhibitor Type 2 Induces IFN-a/b
PAI-2–expressing Cells, but not Control Cells, Showed Con-
stitutive and Inducible Activation of ISGF3. If PAI-2–express-
ing HeLa cells secreted low levels of autocrine IFN-a/b that
was biologically active, then the consequence should be the
presence of constitutively activated ISGF3 in S1b cells.
ISGF3, the complex of ISGF3g and ISGF3a, is the princi-
ple transcription factor activated by IFN-a/b (21). In addi-
tion, PAI-2–expressing cells should also contain ISGF3g, a
protein known to be induced in HeLa cells after priming
with IFN-a/b or -g (36, 37). Control HeLa cells, in con-
trast, lacking significant ISGF3g, should be unable to form
ISGF3 after IFN-a/b or poly IC treatment (36–38).
The predicted presence or absence of active ISGF3 was
determined by EMSA using a radiolabeled oligonucleotide
containing the ISRE to which activated ISGF3 binds (37,
38). EMSA experiments using nuclear extracts showed the
presence of a weak ISGF3 band in S1b cells, which became
more intense after poly IC exposure (Fig. 6 A). The iden-
tity of ISGF3 was confirmed by immunoreactivity of the
complex with anti-ISGF3g antibodies in combination
EMSA/immunoblot experiments (data not shown). ISGF3,
as expected, was undetectable in A2/7 nuclear extracts
from control and poly IC treated cells (Fig. 6 A). These ex-
periments demonstrated that PAI-2 expression resulted in
(a) constitutive low-level ISGF3 activation and (b) induc-
tion of ISGF3g, which permitted enhanced ISGF3 activa-
tion after poly IC treatment. Both of these effects are rec-
ognized consequences of IFN-a/b stimulation (21, 36,
37), strongly suggesting that the low level of autocrine
IFN-a/b was biologically active in S1b cells. The activa-
tion of ISGF3 in S1b cells (but not A2/7 cells) after poly IC
treatment (Fig. 6 A), is consistent with the induction of
IFN-a/b by poly IC seen in Fig. 5 A (38) and provides
further evidence that PAI-2–expressing cells have been
primed by autocrine IFN-a/b exposure.
PAI-2–expressing Cells, but not Control Cells, Showed Con-
stitutive Expression and Nuclear Translocation of ISGF3g. A
series of Western blotting experiments using anti-ISGF3g
antibodies were undertaken to provide further evidence
that PAI-2 expression resulted in constitutive induction of
ISGF3g synthesis, which is normally low or absent in HeLa
cells (36, 37), and in constitutive IFN-a/b–mediated acti-
vation of ISGF3a, which results in the nuclear transloca-
tion of the ISGF3 complex (21, 36, 37, 40). As expected,
control A2/7 cells (No treatment, Fig. 6 B), like the parent
HeLa cells (36, 37), synthesized low to undetectable levels
of ISGF3g and no ISGF3g could be detected in nuclear
extracts. In contrast, S1b cells showed a weak but clear
ISGF3g band in the nuclear extract of resting cells (No
treatment, Fig. 6 B). As a positive control for these experi-
ments, the cells were treated with IFN-g, a known inducer
of ISGF3g (36, 37). As expected IFN-g induced ISGF3g
in both cell lines (IFN-g, Fig. 6 B). Thus as might be ex-
Figure 6. (A) EMSA assay for ISGF3. Nuclear extracts isolated from
S1b and A2/7 cells, either untreated or treated with 20 mg/ml poly IC as
indicated, were analyzed by EMSA using a radiolabeled ISRE oligonucle-
otide probe. The ISGF3 complex detected in S1b cells is indicated by the
arrow. Free probe is shown at the bottom of the gel. The identity of
ISGF3 was confirmed by immunoreactivity of this band with anti-
ISGF3g antibody (data not shown). (B) ISGF3g and IRF-1 expression in
S1b and A2/7 cells. Nuclear and cytoplasmic extracts from S1b and A2/7
cells were analyzed by immunoblotting using antibodies against ISGF3g
and IRF-1. Where indicated, cells were pretreated for 16 h with 500 U/
ml IFN-g. Equal amounts of protein as determined by Bio-Rad protein
assay were loaded in each lane.
Figure 7. Induction of 29-59-
OAS mRNA in S1b and A2/7
cells after RRV infection. (A)
S1b and A2/7 cells (107 cells)
were infected with RRV (MOI
5 1) for the times indicated. To-
tal RNA was isolated and ana-
lyzed by Northern blot using a
32P-radiolabeled OAS cDNA
probe. OAS mRNA is present as
at least three species of 3.6, 1.85,
and 1.65 kb as previously de-
scribed (23). The lower panel
represents the level of 18S rRNA
present in each lane as a control
for loading. (B) Plot of the inten-
sity of the OAS signal in each
lane divided by the intensity of
the 18S rRNA in the same sample.1807 Antalis et al.
pected (36, 37) autocrine IFN-a/b induced expression of
ISGF3g in S1b cells.
The levels of nuclear IRF-1, another transcriptional reg-
ulator of IFN and IFN-regulated genes (21), were also ana-
lyzed in the same extracts by immunoblot analysis. In the
absence of IFN-g treatment, the IRF-1 levels in S1b and
A2/7 extracts were found to be weak and relatively equiv-
alent (Fig. 6 B). However, after IFN-g treatment, less nu-
clear IRF-1 was induced in S1b cells, an observation which
may explain the comparative resistance of these cells to
IFN-g–mediated cytostasis (12).
PAI-2–expressing Cells Were Primed for Rapid Induction of
Antiviral Genes. Although PAI-2–mediated expression of
low-level autocrine IFN-a/b appeared to prime S1b cells
for induction of IFN-a/b after poly IC treatment, this
priming did not result in the induction of IFN-a/b after
RRV infection (Fig. 5 A). To determine whether low-
level autocrine IFN-a/b production in S1b cells (a) in-
duced constitutive expression of antiviral genes or (b)
primed cells for activation of antiviral genes after RRV in-
fection, the synthesis of the IFN-a/b inducible antiviral
gene, 29-59-OAS (24) was monitored by Northern blot
analysis (Fig. 7 A). The antiviral activity of OAS is well
characterized and is mediated by the synthesis of oligoade-
nylate polymers, which activate ribonuclease L, which in
turn degrades viral and cellular RNA (21).
There was no significant difference in the constitutive
levels of OAS mRNA in S1b cells compared with A2/7
cells, indicating that low-level autocrine IFN-a/b produc-
tion in S1b cells was insufficient to upregulate OAS
mRNA in these cells. However, after RRV infection, S1b
cells synthesized significant levels of OAS mRNA within 4 h
of RRV infection, whereas no OAS induction was appar-
ent in A2/7 cells (Fig. 7 B). As RRV infection shuts down
host protein synthesis within 5–8 h, rapid induction of
OAS is likely to be required to protect the cells against
RRV-induced CPE. The drop in the OAS mRNA in S1b
cells at 16 h is consistent with mRNA degradation by acti-
vated ribonuclease L.
These experiments illustrated that, in contrast to control
cells, PAI-2–expressing cells were primed for a rapid in-
duction of the antiviral gene OAS (in the absence of signif-
icant further IFN-a/b production; see Fig. 5, A and B).
This rapid induction of OAS, and perhaps other antiviral
genes, is likely to be responsible for the inhibition of viral
replication (Figs. 2 B and 3) (21) and is likely to be instru-
mental in protecting these cells against CPE (Figs. 1 and 2
A). PAI-2–mediated priming thus conferred on S1b cells
the capacity to produce IFN-a/b after poly IC treatment
and to synthesize OAS after alphavirus infection.
PAI-2 as a Virus Response Gene. PAI-2 is strongly and
rapidly induced by monocytes/macrophages in response to
activation and differentiation agents, e.g., LPS (41) and
PMA (42, 43). The data presented here shows that expres-
sion of PAI-2 can influence viral CPE and IFN-a/b signal-
ing, suggesting that PAI-2 might be involved in the re-
sponse of the monocyte/macrophage to virus infection. To
determine whether macrophages synthesize PAI-2 in re-
sponse to viral infection, PAI-2 mRNA levels were ana-
lyzed in the human macrophage cell line, MonoMac6, after
exposure to neutralized/inactivated RRV, infectious RRV,
RRV in the presence of subneutralizing levels of antisera,
and poly IC (Fig. 8). MonoMac6 cells treated with RRV
alone and RRV plus a 1:10 dilution of antisera (Ab21),
which neutralizes RRV, do not become infected with
RRV. Our previous studies have shown that MonoMac6
cells may be infected with RRV only in the presence of
subneutralizing levels of anti-RRV antibody through an
antibody-dependent enhancement mechanism (16). Thus,
MonoMac6 cells treated with RRV in the presence of sub-
neutralizing dilutions of antibody 1:100 (Ab22), 1:1,000
(Ab23), and 1:10,000 (Ab24) become infected with z15, 5,
and 1% of the cells staining positive by indirect immunofluo-
rescence for RRV after 24 h, respectively (reference 16 and
data not shown). PAI-2 mRNA was induced in all virus-
and poly IC–treated samples irrespective of whether the
cells were infected. In addition, PAI-2 mRNA was in-
duced to levels comparable with those seen after exposure
of MonoMac6 cells to known PAI-2 inducers LPS and
PMA (Fig. 8). These experiments demonstrated that PAI-2
was induced by viral RNA and illustrated that PAI-2 could
be classed as a virus response gene.
Discussion
This study demonstrated that intracellular (Fig. 4) PAI-
2–protected cells from cytopathic alphavirus and adenovi-
rus infections, but not influenza or vaccinia virus infections
(Figs. 1 and 2). The protection against CPE was associated
with a PAI-2–mediated induction of constitutive bioactive
autocrine IFN-a/b production (Figs. 5 and 6), which
primed cells for rapid induction of antiviral genes (Fig. 7).
Thus, after virus infection of PAI-2–transfected HeLa cells,
antiviral genes were rapidly induced (Fig. 7) and this was
associated with a rapid inhibition of viral replication (Figs.
2 B and 3), development of antiviral resistance (Fig. 2 B),
and protection against CPE (Figs. 1 and 2 A). In contrast,
Figure 8. Induction of PAI-2 mRNA in human macrophage
MonoMac6 cells by viral RNA. Total RNA was isolated from z107
MonoMac6 cells after exposure for 4 h to the following: lane 1, un-
treated; lane 2, ultraviolet irradiated, inactivated RRV plus Ab21; lane 3,
RRV infection; lane 4, RRV plus Ab21; lane 5, RRV plus Ab22; lane 6,
RRV plus Ab23; lane 7, RRV plus Ab24; lane 8, 1 mg/ml LPS; lane 9,
40ng/ml PMA; lane 10, 20 mg/ml poly IC. RRV infection was per-
formed at MOI 5 1. RNA was analyzed by Northern blot using a 32P-labeled
probe derived from PAI-2 cDNA. The lower panel represents the level of
18S rRNA present in each lane as a control for loading.1808 Plasminogen Activation Inhibitor Type 2 Induces IFN-a/b
virus infection of control cells did not result in IFN-a/b or
antiviral gene induction and was associated with rapid viral
replication and cell death. This represents the first report of
an association between a mammalian serpin and the regula-
tion of IFN-a/b or IFN-a/b–inducible genes and pro-
vides further evidence for cross-talk between the TNF-a
and IFN-a/b signaling pathways (44, 45). In addition,
PAI-2 was shown to be a virus response gene in macro-
phages (Fig. 8), further supporting the latter contention.
Protection from TNF-a–induced apoptosis and virus-
induced CPE are characteristics that cannot readily be as-
cribed to, or associated with, extracellular PAI-2 activity
(Fig. 4), strongly indicating that the function of intracellular
PAI-2 is entirely distinct from its extracellular role as a uPA
inhibitor.
The reported role for PAI-2 in conferring protection
against apoptosis mediated by TNF-a (11, 12) and Myco-
bacterium avium infection (13) and the reported induction of
apoptosis in neural cells by Sindbis infection (25, 30) sug-
gested that the PAI-2–induced protection seen in Fig. 1
was mediated by a mechanism involving the inhibition of
apoptosis. However, a series of experiments did not sup-
port a role for apoptosis inhibition in the protection against
virus-induced CPE (see Results). In addition, PAI-2 did
not inhibit several caspases involved in the execution of ap-
optosis (reference 12 and our unpublished data). Instead,
our data suggested that PAI-2–mediated protection oc-
curred through a mechanism involving induction of low-
level, autocrine production of IFN-a/b.
A series of data support the contention that PAI-2 ex-
pression induced low-level autocrine IFN-a/b activity,
which primed cells for induction of IFN-a/b and/or anti-
viral genes. In summary, the evidence showed that (a) PAI-
2–expressing cells, but not control cells, were primed for
IFN-a/b production after poly IC treatment (Fig. 5 A); (b)
S1b cells contained elevated mRNA for IFN-a/b (Fig. 5
B); (c) concentrated supernatants from S1b cells, but not
A2/7 cells, conferred protection to A2/7 cells (Fig. 5 C);
(d) long-term incubation of S1b cells with anti–IFN-a/b
antibodies resulted in loss of protection against RRV CPE
(Fig. 5 D); (e) S1b cells, but not A2/7 cells, showed consti-
tutive and inducible activation of ISGF3 (Fig. 6 A), consti-
tutive expression and nuclear localization of ISGF3g (Fig. 6
B); and (f) S1b cells, but not A2/7 cells, showed rapid in-
duction of the IFN-a/b–inducible antiviral gene OAS after
alphaviral infection (Fig. 7). There is considerable prece-
dence for IFN-a/b exposure to prime cells for a rapid anti-
viral response (35, 39), and for primed induction of IFN-a/b–
inducible antiviral genes by virus to occur in the absence of
further IFN-a/b production (see below). Antiviral genes
like OAS are also known to be highly effective in inhibit-
ing alphaviral replication in HeLa cells (32) and other virus
infections generally (21). Importantly, vaccinia and influ-
enza infections in HeLa cells are known to be resistant to
IFN-a/b antiviral activity (32, 33), and PAI-2–expressing
cells were not protected against CPE induced by these vi-
ruses (Fig. 1). In addition, the ability to establish a persistent
infection (Fig. 2 B) is known to be dependent in many in
vitro systems on activation of IFN-a/b–inducible antiviral
genes (34). The reduction in the number of infected S1b
cells seen after initial RRV infection (Fig. 2 B) also illus-
trated that S1b cultures rapidly developed antiviral resis-
tance in response to RRV rather than being somehow in-
nately resistant to infection by this virus.
Cells expressing PAI-2 produced high levels of IFN-a/b
in response to dsRNA (poly IC) and might have been ex-
pected to produce IFN-a/b after RRV infection. How-
ever, viruses and poly IC can stimulate distinct transcrip-
tion factor pathways (46) and IFN-a/b induction is known
to be regulated by multiple independent positive and nega-
tive regulatory elements (21, 35). The exact mechanisms by
which priming and the rapid onset of antiviral resistance
might occur are not well understood. However, constitu-
tive low-level autocrine IFN-a/b priming has been shown
in several cases to be responsible for IFN-a/b–indepen-
dent, rapid, virus-inducible antiviral resistance (47–49).
IFN-a/b priming has been reported to lead to a significant
enhancement of virus-inducible, but IFN-a/b–indepen-
dent, transactivation of IRSFs (which include OAS) through
a mechanism involving IRF-3 (47). Other virus inducible,
IFN-a/b/ISGF3 independent pathways, which can rapidly
induce antiviral resistance genes, are also reported to exist
and involve the dsRNA-activated factors (48) and/or IRF-1
and p91 (49, 50).
The postulated causal link between cytoplasmic expres-
sion of the serpin, PAI-2, and low-level autocrine IFN-a/b
production and the subsequent primed induction of antivi-
ral resistance represents a potentially complex set of interac-
tions between a number of signal transduction pathways.
Whether PAI-2 affects the IFN-a/b pathway directly or
indirectly or whether this effect is independent of the cell
in which PAI-2 is expressed, remains unclear. The molecu-
lar mechanisms responsible for the primed condition are
also poorly understood, although the primed condition ap-
pears to be remarkably stable, taking many days to decay af-
ter removal of IFN (40). IFN priming is well recognized in
many cells, but priming may have distinct molecular and
phenotypic consequences in different cell types and under
different conditions (51). Despite these complexities, the
two phenotypes of PAI-2–expressing cells, resistance to
TNF-a–mediated apoptosis and induction of IFN-a/b
priming, suggest that PAI-2 can influence a signaling path-
way common to both the TNF-a and IFN-a/b pathways.
Addition of IFN-a–2B to HeLa or A2/7 cells did not ren-
der them resistant to TNF-a–induced apoptosis (data not
shown), indicating that protection of PAI-2–expressing
cells against TNF-a–induced apoptosis was not a direct
consequence of low-level IFN-a/b production. That cross-
talk exists between the TNF-a and IFN-a/b pathways has
recently been demonstrated (44, 45) and may involve dou-
ble-stranded RNA activated protein kinase. One might
speculate that the NF-kB signaling complex, which plays
an important role in promoting survival after TNF-a acti-
vated signal transduction (52), may be the target of PAI-21809 Antalis et al.
action as NF-kB is also the primary regulator of IFN-b
synthesis (21). Production of both IFN-a and IFN-b
might then occur via positive feedback through activation
of ISGF3 (38). The demonstration of PAI-2–mediated in-
fluences on transcription factor pathways indicates that the
levels of certain transcription factors might be regulated by
the activity of specific cytoplasmic proteinases (53), which
may in turn be controlled by specific proteinase inhibitors.
The ability of virus and poly IC to induce PAI-2 in the
monocyte line, MonoMac6, suggests that PAI-2 induction
may be a physiological response to viral RNA. Similar in-
duction of PAI-2 expression has been reported after Dengue
virus infection of primary monocytes (54). TNF-a is a pri-
mary inducer of PAI-2 (55), however, virus-induced auto-
crine TNF-a production by MonoMac6 cells is unlikely to
cause PAI-2 induction in these cells, since RRV infection
of MonoMac6 cells did not result in the release of detect-
able TNF-a (16). The presence of an IFN-g activation se-
quence (GAS)–like element in the upstream promoter re-
gion of PAI-2 (56) might suggest that PAI-2 represents an
IFN-a/b response gene, perhaps activated by IFN-a/b–
activated STAT1–STAT2 heterodimers, which have re-
cently been shown to bind to GAS elements (57).
PAI-2 thus appears to have a physiological intracellular
role as a regulator of a cellular signaling pathway(s), which
results in at least two phenotypes, resistance to TNF-a–medi-
ated apoptosis, and induction of low-level autocrine IFN-a/b.
For activated macrophages in an inflammatory site, such
phenotypes would clearly be advantageous, conveying the
ability to resist both autocrine TNF-a and to be primed for
rapid antiviral responses. The other major site of intracellu-
lar PAI-2 expression is in epidermal keratinocytes (58),
where synthesis of PAI-2 is constitutive. These cells may
also express constitutive IFN-a/b (59) and are a major
source of TNF-a after trauma to the skin (60). Constitu-
tive PAI-2 expression in keratinocytes may thus have a
similar role to that postulated for macrophages, priming
these cells for rapid responses to invading pathogens and
protecting them against autocrine TNF-a.
Viral induction of PAI-2 and the PAI-2–mediated estab-
lishment of a persistent infection may also point to a poten-
tial pathological role for PAI-2. Persistence of organisms in
macrophages is implicated in the pathogenesis of several
diseases including HIV (61) and certain chronic infectious
arthritides, including epidemic polyarthritis, which is caused
by RRV (16).
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